{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T11:56:49Z","timestamp":1792065409509,"version":"4.4.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T00:00:00Z","timestamp":1777766400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurolog\u00eda (English Edition)"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.nrleng.2026.502081","type":"journal-article","created":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T21:31:41Z","timestamp":1777930301000},"page":"502081","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Barriers to access to anti-CGRP monoclonal antibodies in Spain: survey of neurologists, hospital pharmacists, and patients"],"prefix":"10.1016","volume":"41","author":[{"given":"P.","family":"Irimia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"D\u00edaz-Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Colomina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Belv\u00eds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.M.","family":"Lainez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.nrleng.2026.502081_bib0005","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1177\/0333102410382794","article-title":"One-year prevalence of migraine in Spain: a nationwide population-based survey","volume":"31","author":"Mat\u00edas-Guiu","year":"2011","journal-title":"Cephalalgia"},{"issue":"2","key":"10.1016\/j.nrleng.2026.502081_bib0010","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/s41582-022-00763-1","article-title":"Global epidemiology of migraine and its implications for public health and health policy","volume":"19","author":"Steiner","year":"2023","journal-title":"Nat Rev Neurol"},{"issue":"4","key":"10.1016\/j.nrleng.2026.502081_bib0015","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/S1474-4422(24)00038-3","article-title":"Global, regional, and national burden of disorders affecting the nervous system, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021","volume":"23","year":"2024","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.nrleng.2026.502081_bib0020","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1111\/ene.14431","article-title":"Estimating the savings associated with a migraine-free life: results from the Spanish Atlas","volume":"27","author":"Irimia","year":"2020","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.nrleng.2026.502081_bib0025","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s10194-024-01740-3","article-title":"Societal and economic burden of migraine in Spain: results from the 2020 National Health and Wellness Survey","volume":"25","author":"Garc\u00eda-Azor\u00edn","year":"2024","journal-title":"J Headache Pain"},{"key":"10.1016\/j.nrleng.2026.502081_bib0030","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.nrl.2019.03.013","article-title":"Calcitonin gene\u2014related peptide in migraine: from pathophysiology to treatment CGRP en migra\u00f1a: de la fisiopatolog\u00eda a la terap\u00e9utica","volume":"37","author":"Santos-Lasaosa","year":"2022","journal-title":"Neurologia (Engl Ed)"},{"key":"10.1016\/j.nrleng.2026.502081_bib0035","unstructured":"Ministerio de Sanidad, Consumo y Bienestar Social, Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios. Informe de Posicionamiento Terap\u00e9utico de erenumab (Aimovig\u00ae) en la profilaxis de migra\u00f1a. IPT 62\/2019 V1. 15 de noviembre de 2019 [Accessed 20 May 2024]. Available from: https:\/\/www.aemps.gob.es\/medicamentosUsoHumano\/informesPublicos\/docs\/IPT-erenumab-Aimovig.pdf."},{"key":"10.1016\/j.nrleng.2026.502081_bib0040","unstructured":"Ministerio de Sanidad, Consumo y Bienestar Social. Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios. Informe de Posicionamiento Terap\u00e9utico de galcanezumab (Emgality\u00ae) en la profilaxis de migra\u00f1a. IPT 63\/2019 V1. 15 de noviembre de 2019 [Accessed 20 May 2024]. Available from: https:\/\/www.aemps.gob.es\/informa\/informes-de-posicionamientoterapeutico\/informe-deposicionamiento-terapeutico-defremanezumab-ajovy-en-la-profilaxis-de-migrana\/."},{"key":"10.1016\/j.nrleng.2026.502081_bib0045","unstructured":"Ministerio de Sanidad, Consumo y Bienestar Social. Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios. Informe de Posicionamiento Terap\u00e9utico de fremanezumab (Ajovy\u00ae) en la profilaxis de migra\u00f1a. IPT, 11\/2020. V1. 3 de noviembre de 2020 [Accessed 20 May 2024]. Available from: https:\/\/www.aemps.gob.es\/informa\/informesde-posicionamiento-terapeutico\/informede-posicionamientoterapeutico-de-fremanezumab-ajovy-en-la-profilaxis-demigrana\/."},{"issue":"8","key":"10.1016\/j.nrleng.2026.502081_bib0050","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.nrl.2022.08.004","article-title":"Inequity of access to new migraine treatments","volume":"38","author":"Irimia","year":"2023","journal-title":"Neurologia (Engl Ed)"},{"issue":"1","key":"10.1016\/j.nrleng.2026.502081_bib0055","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s12883-024-03600-8","article-title":"Migraine treatment: quo vadis? Real-world data study (2015-2022) in Spain","volume":"24","author":"Pozo-Rosich","year":"2024","journal-title":"BMC Neurol"},{"issue":"5","key":"10.1016\/j.nrleng.2026.502081_bib0060","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1007\/s40122-023-00538-6","article-title":"Burden and Unmet Needs in Migraine Patients: Results from the OVERCOME (Spain) Study","volume":"12","author":"Pascual","year":"2023","journal-title":"Pain Ther"},{"issue":"6","key":"10.1016\/j.nrleng.2026.502081_bib0065","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.farma.2023.03.011","article-title":"Consensus recommendations for the treatment of migraine prevention","volume":"47","author":"Calleja-Hern\u00e1ndez","year":"2023","journal-title":"Farm Hosp"},{"key":"10.1016\/j.nrleng.2026.502081_bib0070","unstructured":"AEMICE, el Consejo General de Colegios Oficiales de Farmac\u00e9uticos (CGCOF), y las sociedades espa\u00f1olas de Neurolog\u00eda (SEN), de Medicina de Urgencias y Emergencias (SEMES), de M\u00e9dicos de Atenci\u00f3n Primaria (SEMERGEN), de Farmacia Hospitalaria (SEFH) y de Enfermer\u00eda Neurol\u00f3gica (SEDENE). Libro blanco de la migra\u00f1a en Espa\u00f1a. [Accessed 20 May 2024]. Available from: https:\/\/www.dolordecabeza.net\/wp-content\/uploads\/2021\/11\/Libro_Blanco_Migrana_Espana_2021.pdf"},{"issue":"2","key":"10.1016\/j.nrleng.2026.502081_bib0075","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1177\/03331024211053571","article-title":"Erenumab versus topiramate for the prevention of migraine - a randomised, double-blind, active-controlled phase 4 trial","volume":"42","author":"Reuter","year":"2022","journal-title":"Cephalalgia"},{"key":"10.1016\/j.nrleng.2026.502081_bib0080","doi-asserted-by":"crossref","DOI":"10.1001\/jamaneurol.2024.0368","article-title":"Early Use of Erenumab vs Nonspecific Oral Migraine Preventives: The APPRAISE Randomized Clinical Trial","author":"Pozo-Rosich","year":"2024","journal-title":"JAMA Neurol."},{"issue":"10","key":"10.1016\/j.nrleng.2026.502081_bib0085","first-page":"927","article-title":"Redefining migraine prevention: early treatment with anti-CGRP monoclonal antibodies enhances response in the real world","volume":"95","author":"Caronna","year":"2024","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"10.1016\/j.nrleng.2026.502081_bib0090","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s10194-022-01448-2","article-title":"Persistence, use of resources and costs in patients under migraine preventive treatment: the PERSEC study","volume":"23","author":"Irimia","year":"2022","journal-title":"J Headache Pain"},{"issue":"1","key":"10.1016\/j.nrleng.2026.502081_bib0095","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s10194-023-01682-2","article-title":"Impact of a reimbursement policy change on treatment with erenumab in migraine - a real-world experience from Germany","volume":"24","author":"Hong","year":"2023","journal-title":"J Headache Pain"},{"issue":"1","key":"10.1016\/j.nrleng.2026.502081_bib0100","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s10194-024-01727-0","article-title":"Early and annual projected savings from anti-CGRP monoclonal antibodies in migraine prevention: a cost-benefit analysis in the working-age population","volume":"25","author":"Lazaro-Hernandez","year":"2024","journal-title":"J Headache Pain"},{"key":"10.1016\/j.nrleng.2026.502081_bib0105","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s10194-022-01431-x","article-title":"European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention-2022 update","volume":"23","author":"Sacco","year":"2022","journal-title":"J Headache Pain"},{"issue":"4","key":"10.1016\/j.nrleng.2026.502081_bib0110","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/head.14692","article-title":"Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: An American Headache Society position statement update","volume":"64","author":"Charles","year":"2024","journal-title":"Headache"}],"container-title":["Neurolog\u00eda (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173580826000714?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173580826000714?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T11:34:48Z","timestamp":1792064088000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2173580826000714"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":22,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S2173580826000714"],"URL":"https:\/\/doi.org\/10.1016\/j.nrleng.2026.502081","relation":{},"ISSN":["2173-5808"],"issn-type":[{"value":"2173-5808","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Barriers to access to anti-CGRP monoclonal antibodies in Spain: survey of neurologists, hospital pharmacists, and patients","name":"articletitle","label":"Article Title"},{"value":"Neurolog\u00eda (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nrleng.2026.502081","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.nrl.2026.502081","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Sociedad Espa\u00f1ola de Neurolog\u00eda. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"502081"}}